Institutional asset managers, dedicated biotechnology venture capital funds, and specialized healthcare investment firms hold the majority of equity shares in Tenaya Therapeutics. Major institutional stakeholders include prominent asset management firms, venture funds associated with its founding incubation, and corporate insiders whose holdings align with the long-term clinical development of its cardiovascular gene therapy portfolio.